iCAD will showcase the latest technology and research on its Xoft Axxent electronic brachytherapy system at the American Society for Radiation Oncology (ASTRO) virtual annual meeting.
During the ASTRO 2020, the virtual Xoft booth will feature a full suite of applicators for existing and emerging applications for the 50-kV radiation oncology treatment device.
The company will also host virtual discussions on electronic brachytherapy and intraoperative radiation therapy (IORT), with two researchers presenting studies on the use of the Xoft device at ASRO. The studies found Xoft benefited patients with early-stage breast cancer and gynecological cancer.
In one study, presenter Dr. A.M. Nisar Syed and colleagues conducted a multicenter trial using intraoperative electronic brachytherapy for breast cancer. The trial included 1,200 patients and found IORT with Xoft was safe and had low local recurrence, according to iCAD.
In the second study, presenter Dr. Arantxa Campos and colleagues enrolled 236 patients in a trial evaluating Xoft electronic brachytherapy for endometrial cancer treatment. The team concluded Xoft could serve as a feasible alternative to high-dose-rate brachytherapy, iCAD noted.
